Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma

Journal of Clinical Pathology

Volumn 65, Issue 8, 2012, Pages 735-739

  Jang, Si Hyong ^a   Min, Kyeung Whan ^a   Paik, Seung Sam ^a   Jang, Ki Seok ^a  

^a Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MLH1; PROTEIN MSH2; SIRTUIN 1;

ADENOMATOUS POLYP; ADULT; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER LOCALIZATION; CANCER SURVIVAL; CARCINOGENESIS; COLON MUCOSA; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; DISTANT METASTASIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADENOMATOUS POLYPS; CELL TRANSFORMATION, NEOPLASTIC; CHI-SQUARE DISTRIBUTION; COLONIC POLYPS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SIRTUIN 1; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864549056     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200685     Document Type: Article

References (26)

1. Imai S, Armstrong CM, Kaeberlein M, et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000;403:795-800. (Pubitemid 30111843)
2. Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 2000;289:2126-8.
3. Bordone L, Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol 2005;6:298-305. (Pubitemid 40516896)
4. Chen D, Steele AD, Lindquist S, et al. Increase in activity during calorie restriction requires Sirt1. Science 2005;310:1641. (Pubitemid 41780779)
5. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-59. (Pubitemid 33035942)
6. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004;305:1010-13. (Pubitemid 39071777)
7. Ford J, Jiang M, Milner J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 2005;65:10457-63. (Pubitemid 41743740)
8. Backesjo CM, Li Y, Lindgren U, et al. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res 2006;21:993-1002. (Pubitemid 43962828)
9. Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2006;2:e40.
10. Fang Y, Nicholl MB. Sirtuin 1 in malignant transformation: friend or foe? Cancer Lett 2011;306:10-14.
11. Chen WY, Wang DH, Yen RC, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005;123:437-48. (Pubitemid 41546674)
12. Zhao W, Kruse JP, Tang Y, et al. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 2008;451:587-90. (Pubitemid 351186268)
13. Huffman DM, Grizzle WE, Bamman MM, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007;67:6612-18. (Pubitemid 47105506)
14. Bradbury CA, Khanim FL, Hayden R, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005;19:1751-9. (Pubitemid 41486152)
15. Hida Y, Kubo Y, Murao K, et al. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res 2007;299:103-6. (Pubitemid 46669407)
16. Firestein R, Blander G, Michan S, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008;3:e2020.
17. Wang RH, Zheng Y, Kim HS, et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell 2008;32:11-20.
18. Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008;14:312-23.
19. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 2009;69:1702-5.
20. Herranz D, Munoz-Martin M, Canamero M, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 2010; 1:1-8.
21. Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer 2010;10:819-23.
22. Cha EJ, Noh SJ, Kwon KS, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 2009;15:4453-9.
23. Jang KY, Hwang SH, Kwon KS, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 2008;32:1523-31.
24. Jang KY, Kim KS, Hwang SH, et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 2009;41:366-71.
25. Nosho K, Shima K, Irahara N, et al. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2009;22:922-32.
26. Kabra N, Li Z, Chen L, et al. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 2009;284:18210-17.